

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/005350-2024>

Opportunity

NHS Framework - Blood Disorders including Haemophilia A and B - July 2024

NHS England

F02: Contract notice

Notice reference: 2024/S 000-005350

Published: 19 February 2024, 11:12am

Section I: Contracting authority

I.1) Name and addresses

NHS England

1st Floor, Quarry House, Quarry Hill

Leeds

LS2 7UE

Contact

Katie Noonan

Email

katie.noonan@nhs.net

Country

United Kingdom

NUTS code

UKE - Yorkshire and the Humber

Internet address(es)

Main address

<https://www.england.nhs.uk//>

Buyer's address

<https://www.england.nhs.uk//>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://health-family.force.com/s/Welcome>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://health-family.force.com/s/Welcome>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://health-family.force.com/s/Welcome>

I.4) Type of the contracting authority

Ministry or any other national or federal authority

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NHS Framework - Blood Disorders including Haemophilia A and B - July 2024

Reference number

CM/PHS/22/5561

II.1.2) Main CPV code

- 33600000 - Pharmaceutical products

II.1.3) Type of contract

Supplies

II.1.4) Short description

Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024

Offer reference number: CM/PHS/22/5561

Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.

Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

II.1.5) Estimated total value

Value excluding VAT: £1,168,000,000

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

II.2) Description

II.2.1) Title

CM/PHS/22/5561/01 Standard Half-life Recombinant Factor VIII

Lot No

1

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

Standard Half-life Recombinant Factor VIII

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/02 Enhanced Half-life Recombinant Factor VIII

Lot No

2

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/02 Enhanced Half-life Recombinant Factor VIII

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/03 Emicizumab

Lot No

3

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/03 Emicizumab

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/04 eftrenonacog alfa (rFIX EHL)

Lot No

4

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/04 eftrenonacog alfa (rFIX EHL)

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/05 albutrepenonacog alfa (rFIX EHL)

Lot No

5

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/05 albutrepenonacog alfa (rFIX EHL)

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/06 nonacog beta pegol (rFIX EHL)

Lot No

6

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/06 nonacog beta pegol (rFIX EHL)

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/07 rFIX - Standard Half Life

Lot No

7

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/07 rFIX - Standard Half Life

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/08 Recombinant Factor VII

Lot No

8

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/08 Recombinant Factor VII

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement

documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/09 Porcine Factor VIII - susoctocog alfa

Lot No

9

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/09 Porcine Factor VIII - susoctocog alfa

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/10 Factor VIII Inhibitor Bypassing Fraction

Lot No

10

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/10 Factor VIII Inhibitor Bypassing Fraction

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/11 Factor IX - High Purity Factor IX

Lot No

11

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/11 Factor IX - High Purity Factor IX

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing

system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/12 Factor X

Lot No

12

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/12 Factor X

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/13 Factor XIII - Plasma Derived

Lot No

13

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/13 Factor XIII - Plasma Derived

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/14 Factor XIII - Recombinant

Lot No

14

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/14 Factor XIII - Recombinant

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/15 Von willebrands factor / Factor VIII

Lot No

15

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/15 Von willebrands factor / Factor VIII

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/16 Von willebrands factor - Plasma Derived

Lot No

16

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/16 Von willebrands factor - Plasma Derived

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing

system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/17 Von willebrands factor - Recombinant

Lot No

17

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/17 Von willebrands factor - Recombinant

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/18 Fibrinogen Concentrate

Lot No

18

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/18 Fibrinogen Concentrate

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/19 Prothrombin Complex dried

Lot No

19

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/19 Prothrombin Complex dried

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/20 Protein C Concentrate

Lot No

20

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/20 Protein C Concentrate

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups)

Lot No

21

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups)

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing

system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/22 Freeze Dried Plasma

Lot No

22

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/22 Freeze Dried Plasma

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

CM/PHS/22/5561/23 Caplacizumab

Lot No

23

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

II.2.4) Description of the procurement

CM/PHS/22/5561/23 Caplacizumab

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2024

End date

30 April 2027

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

There will be an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III. Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

21 March 2024

Local time

1:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Tender must be valid until: 19 June 2024

IV.2.7) Conditions for opening of tenders

Date

21 March 2024

Local time

1:00pm

Place

Runcorn

Information about authorised persons and opening procedure

Medicines Procurement and Supply Chain Employee

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.2) Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

VI.3) Additional information

RESPONDING TO THIS NOTICE;

Any supplier may be disqualified who does not respond to the following in the requisite manner:

1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at

<http://health.atamis.co.uk>

Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:

1.1) If not already registered, Candidates should register on the eTendering portal at

<http://health.atamis.co.uk> and click the link to register:

- agree to the user agreement
- populate company details

1.2) Once registered, candidates must register interest as follows:

- log to the portal
- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select
- review opportunity details and click "Register Interest"
- as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity)

1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis helpdesk at supporthealth@atamis.co.uk or by calling 0800 9956035 for technical assistance when completing responses.

2) General supplier information.

To manage and assess supplier information the Contracting Authority requests candidates provide their

company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:

2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page

<https://supplierregistration.cabinetoffice.gov.uk>

and select "Register" at the top of the page.

Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B.

Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.

2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.

D&B data will be supplied automatically by D&B.

2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the

message function on the website.

OTHER CONTRACTING AUTHORITIES

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

VI.4) Procedures for review

VI.4.1) Review body

The High Court

The Strand

London

WC2A 2LL

Country

United Kingdom

Internet address

<https://www.judiciary.uk/courts-and-tribunals/high-court/>